<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clinical manifestations of most <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> have changed over the past few decades, largely due to advances in therapies targeting autoimmune and (auto)inflammatory pathways </plain></SENT>
<SENT sid="1" pm="."><plain>Improvements in the management of <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> have also now brought to the fore the issue of comorbidities </plain></SENT>
<SENT sid="2" pm="."><plain>It has become evident that the burden of <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality is increased in <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and the <z:e sem="disease" ids="C0949691" disease_type="Disease or Syndrome" abbrv="SPDA1">spondyloarthropathies</z:e>, amongst other conditions </plain></SENT>
<SENT sid="3" pm="."><plain>As a result, efforts have switched toward investigating the effects of conventional antirheumatic and new biologic agents on inflammationinduced atherothrombosis </plain></SENT>
<SENT sid="4" pm="."><plain>Evidence is accumulating suggesting a beneficial cardiovascular profile of some <z:chebi fb="0" ids="35842">antirheumatic drugs</z:chebi>, such as <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and hydroxychloroquine, but it also indicates the possibility of a variety of adverse events developing in the short- and long-term </plain></SENT>
<SENT sid="5" pm="."><plain>The aim of this review is to highlight cardiovascular adverse effects of the drugs widely used in the treatment of <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The literature search was performed through PubMed, the Cochrane Library, Scopus, and Web of Science databases using the following terms: "<z:chebi fb="0" ids="35842">antirheumatic drugs</z:chebi>", "<z:mp ids='MP_0001845'>inflammation</z:mp>", "<z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e>", "<z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e>", "adverse events", "toxicity", "drug design", and "drug interactions" </plain></SENT>
<SENT sid="7" pm="."><plain>Adverse events ranging from infusion-related <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>, to <z:hpo ids='HP_0001723'>restrictive cardiomyopathy</z:hpo> and <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> have been reported in large trials and case series on most <z:chebi fb="0" ids="35842">antirheumatic drugs</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Clinicians should be alert of the wide variety of cardiovascular adverse effects of individual <z:chebi fb="0" ids="35842">antirheumatic drugs</z:chebi>, and should carefully monitor blood pressure and markers of <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:mp ids='MP_0005048'>thrombosis</z:mp>, <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>, electrolytes, and <z:chebi fb="23" ids="18059">lipid</z:chebi> disturbances while administering these drugs </plain></SENT>
<SENT sid="9" pm="."><plain>Future prospective studies should specifically investigate the cardiovascular safety of most <z:chebi fb="0" ids="35842">antirheumatic drugs</z:chebi> as part of mono- or combination therapy in relation to different dosage regimens, duration of therapy, age, and gender </plain></SENT>
</text></document>